NASA video of moon rocket test shows something just went seriously wrong
Northrop Grumman, lead contractor for the booster, conducted the two-minute ground test of the solid rocket motor, which was strapped down sideways. For the first 1.5 minutes, the motor — known as NASA's Booster Obsolescence and Life Extension, or BOLE — seemed to be working fine. Seconds later, debris blew out of the nozzle and flames rippled through the long exhaust plume.
The 156-foot booster kept firing through the remainder of the test, and no one was hurt. NASA's livestream, which you can watch below, caught the incident, starting at about 22 minutes and 17 seconds into the video.
Engineers didn't immediately acknowledge the issue during that broadcast, apart from one controller uttering "Whoa," followed by an audible gasp. The company later confirmed a problem occurred late in the burn, though representatives didn't elaborate on what went wrong.
The anomaly, which took place at a Northrop Grumman test facility in Promontory, Utah, raises questions about the hardware that could one day send astronauts into space — and potentially to Mars.
"As a new design, and the largest segmented solid rocket booster ever built, this test provides us with valuable data to iterate our design for future developments," said Jim Kalberer, Northrop Grumman's vice president of propulsion systems, in a statement.
SEE ALSO: Webb telescope smashed a record with the planet it just discovered
A single BOLE booster produces more than 4 million pounds of thrust. Credit: Northrop Grumman
The BOLE motor is a major redesign of the ones used on NASA's Space Launch System, or SLS, the rocket built to carry astronauts to the moon under the Artemis program. It swaps out old parts with lightweight materials and new fuel, giving it more thrust and allowing the rocket to haul heavier loads.
The boosters for the first eight flights of Artemis repurpose the steel booster cases and other parts from the Space Shuttle program. Beginning with Artemis IX, the SLS rocket, sometimes dubbed the mega moon rocket, is supposed to use the BOLE. The plan is for two of them to flank either side of the rocket.
"In order to save cost and schedule, we implemented the Shuttle's proven heritage hardware into our design, but this is being depleted as the Artemis program progresses," said Julia Khodabandeh, NASA's deputy manager for the SLS booster element office. "It's just not practical to restart the manufacturing from that 1970s era."
This was the first demonstration test of the enhanced five-segment solid rocket motor. That single booster produced more than 4 million pounds of thrust, said Dave Reynolds, NASA's SLS booster subsystems manager.
"You can see from the side of the mountain up there," Reynolds said afterward, "it's still feeling the effects of that test."
The purpose of the demonstration was to test the limits of the motor's design, understand the stress and strain on different materials, and see if the motor's components could withstand extreme conditions. The two-minute test mimics the time a booster would fire during a real launch. Northrop Grumman officials said the data from the BOLE test will help improve the design.
The new boosters are not expected to fly until at least the late 2030s, and it's unclear whether they ever will. Proposed budget cuts for NASA would mean SLS production ceases after Artemis III, the first human moon landing since Apollo 17. That mission has been postponed until 2027 at the earliest.
The White House has said it would like to see the space agency focus instead on using commercial systems. Lawmakers are still debating how many more SLS launches, about $4.1 billion each, to fund.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Peeing In A Pool Is Gross, But Is It Really All That Bad? Here's What Science Says.
You know you shouldn't pee in the pool, but you probably do it anyway. But at what cost? Do you even know? There are no hard-and-fast numbers on how often people pee in the pool, but at least one survey got 40% of American adults to admit to peeing in the pool. It doesn't seem like they're exaggerating: Older research published in the journal Environmental Science & Technology Letters analyzed water samples from 31 pools and hot tubs and discovered that a 220,000-gallon pool contained about 20 gallons of pee. Related: With that, the odds of you swimming in pee this summer are high. While peeing in the pool is gross, is it really all that bad? What can happen if you or someone around you does this just once? In the name of science, we tapped a toxicologist, infectious disease physician and microbiologist to break it all down. Related: What happens when you pee in a pool? A few things. The big issue is the interaction of urine with the chemicals in the pool. 'When human urine combines with chemicals that are present in chlorinated swimming pools, potentially harmful compounds called disinfection byproducts, or DBPs, can form,' said Dr. Kelly Johnson-Arbor, a toxicologist at MedStar Health. Urine naturally contains nitrogen-containing compounds like urea, ammonia and creatinine, Johnson-Arbor explained. 'These nitrogen-rich compounds can react with chlorine or other disinfectants found in swimming pools to form DBPs that can cause harmful health effects.' Chlorine specifically forms something called chloramines when it binds to human waste products (like pee) in the pool, according to the Centers for Disease Control and Prevention. These chloramines can build up in the water and off-gas into the air. This isn't just a urine thing. 'Chlorine interacts with many kinds of organic matter,' said Thomas Melendy, associate professor of microbiology and immunology, and biochemistry in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in New York. 'The reason it's put in pools is to act as an antibacterial and antiviral. It helps to keep the pool clean and noninfectious.' How big of a deal is it? It depends on how you look at it. 'From an infectious disease point of view, peeing in a well-chlorinated pool doesn't really present a problem. That's not to be confused with pooping in the pool, which does,' said Dr. Thomas Russo, professor and chief of infectious disease at the University at Buffalo. While urine isn't sterile, most people don't carry major pathogens in their pee that chlorine can't handle, Russo said. But chloramines can be an issue, according to Melendy. 'Any time chlorine interacts with organic matter, it makes chloramines,' he said. 'The more chloramines that are produced, the higher the risk of skin, eye and lung irritation.' (This can be a bigger problem in people with underlying respiratory issues such as asthma, he said.) Related: If ventilation in an area isn't great, chloramines that off-gas from the water will settle on the water's surface, where they can cause symptoms, according to the CDC. One of those chloramines is trichloramine, a volatile chemical that evaporates easily into the air and causes that signature 'chlorine' smell in swimming pools, Johnson-Arbor said. The more organic matter in the pool, the more chloramines are produced, Melendy said. (That includes pee, along with sweat and poop particles.) This also inactivates the chlorine, he points out. 'The more organic matter you introduce to the pool, the less effective chlorine is at being an antibacterial because it gets used up,' Melendy said. What if you pee in a saltwater pool? The impact is likely the same, Johnson-Arbor said. 'Saltwater pools use electrochemically generated chlorine instead of liquid chlorine for disinfection,' Johnson-Arbor said. (Electrochemically generated chlorine happens after an electric current is passed through a concentrated salt solution.) 'Since this process still generates chlorine, any nitrogen-containing matter that is present in a saltwater pool can still combine with the chlorine to generate DBPs,' Johnson-Arbor said. What if only one person pees in the pool? If you really have to go and there's no bathroom nearby, it's fair to wonder how much of an issue it will be if just one person pees in the pool. 'It's a matter of concentration,' Melendy said. 'There's so much chlorine and water in the pool. If just one person pees in a very large pool, it's unlikely to create a significant irritant.' (However, he points out that sensitivity varies from person to person.) Related: 'If it's one person in a really small pool, it might have a significant impact,' Melendy said. 'Conversely, if it's a big pool and a lot of people are doing it, it's going to produce lots of chloramine gases. This is a nuanced thing.' Johnson-Arbor also pointed out that this isn't just a urine issue. Sweat and poop particles inevitably slip off your skin and into the water, too. 'In addition, if individuals do not shower before entering pools, their loose hairs and skin cells can transfer from their bodies into the pool, further contributing to development of DBPs,' Johnson-Arbor said. Ultimately, doctors recommend taking a pass on peeing in the pool. 'Public health perspective aside, it's just bad behavior,' Russo said. Related... Doctors Are Getting Bombarded With 'Photo Dumps' Of Patients' Poop Pics — Here's Why Does Your Poop Sink? Here's What It Could Say About Your Health. So THAT'S Why You Always Need To Pee When You Get Close To Home


Fox News
3 hours ago
- Fox News
Ken Ham's Unwavering Belief That Science Bows to the Authority of Scripture
Ken Ham, the man behind the Creation Museum and the Ark Encounter, is also the person media loves to hold up as an example of why people shouldn't believe the Bible. Specifically, what's targeted is his belief in a young earth, one that is a few thousand years old as opposed to more than 4.5 billion years old. Yet Ham never wavers from his belief in what the Bible says about creation, the age of the earth, evolution, and the like. On this episode of the Lighthouse Faith podcast, Ham doubles down on his conviction in the authority of the Bible in all things, and yes, even science. For instance, Ham says that regardless of what science has discovered about light may not be the complete picture of its inimitable qualities. The Bible says God created light, 'And God said, 'Let there be light.'' But what God didn't tell us in Genesis is of light's wave/particle duality, or that the speed of light is 671 million miles per hour. Ham is a scientist; one who looks at the exact same data as any other trained expert. The difference is that, because of his belief in the authority of the Bible, Ham's conclusions diverge from conventional scientific thought. Learn more about your ad choices. Visit